Skip to main content
. 2020 Apr 3;10:435. doi: 10.3389/fonc.2020.00435

Figure 5.

Figure 5

Comparison of cytotoxic effect and selectivity of IACS-010759/vinorelbine and rotenone/2-deoxy-D-glucose drug pairs with cytarabine/doxorubicin by trypan blue exclusion. (A,B) Drug combination landscapes for AML cell lines or PBMCs were built using Bioconductor package “synergyfinder.” One representative replicate (with maximal synergy closest to its average value) is shown: (A) cytarabine/doxorubicin, (B) IACS-010759/vinorelbine. (C–E) Survival of MOLM-13, OCI-AML2, or healthy PBMCs following single or combinatorial treatments with doses of maximal selectivity: (C) cytarabine/doxorubicin, (D) IACS-010759/vinorelbine, (E) rotenone/2-deoxy-D-glucose. Shown are mean ± SEM from three independent biological replicates. Significance of changes in survival were assessed via Student's t-test. ***p < 0.001; **p < 0.01; *p < 0.05; ns: p > 0.05. Black stars or ns indicate comparison of AML cells vs. healthy PBMCs under the same treatment condition; purple stars indicate significantly lower survival under combinatorial treatment compared to single mitocan for each cell line; orange stars indicate significantly lower survival under combinatorial treatment compared to single complementary drug for each cell line.